Safety and Efficacy of the Metabolic Profiling of the BIMRT Utilizing 18F FDG PET-CT

Abstract

Aim: This study aims to evaluate the safety and efficacy of fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) guided intensity-modulated radiation therapy (IMRT) for patients with peritoneal metastases. Patients and Methods: A total of 55 patients with peritoneal metastases were treated with 18F-FDG-PET/CT-guided IMRT (BIMRT) from January 2012 to January 2019. They were prescribed with a fraction of the median dose of 2 Gy to a total dose of 50.4 Gy. The multivariate analysis was used the Cox proportional hazard model and the Kaplan-Meier plot was used to perform local control rate (LCR), progression-free survival (PFS), and overall survival (OS) analysis. Results: The 1-year, 2-year, and 3-year LCR were 72.7%, 36.4%, and 9.1%, respectively; the 1-year, 2-year, and 3-year PFS were 69.1%, 30.9%, and 7.3%, respectively, and the median PFS time was 18 months. The 1-year, 3-year and 5-year OS were 70.9%, 28.7%, and 4.2%, respectively. Based on the multivariate analysis using the Cox proportional hazard model, the Karnofsky performance status (KPS) score and radiotherapy joint chemotherapy (RJC) method were independent prognostic-related indicators (P < 0.0001). Conclusion: BIMRT may be a safe and effective treatment for patients with peritoneal metastases, especially for patients who cannot undergo surgery. In addition, the results indicated that the patient’s KPS score and RJC method were independent prognostic-related indicators for patients survival time.

Monitoring the hepatobiliary function using image techniques and labeled cholephilic compounds

“…Although the use of radiolabeled probes is not exempt from risks, this is clinically acceptable. Indeed, even used at therapeutical doses, the toxicity induced by 18 F-FDG, for instance, is limited to acute and reversible mild gastrointestinal and hematological side effects [79].…”

Advances in Cytoreductive Surgery and Combination Therapy for Ovarian Cancer

“…Concurrent chemoradiotherapy for advanced ovarian cancer, especially for elderly patients, has been shown to be effective in the near term when surgery and chemotherapy are not suitable. At present, there are few studies on Biological Intensity Modulated Radiation Therapy (BIMRT) therapy [46], but it has been confirmed that BIMRT can improve the quality of life of cancer patients and is well tolerated. Dang et al [47] reported that a 68-year-old female patient with ovarian cancer with abdominal metastasis received concurrent radiotherapy and chemotherapy with the tumor disappearing and the tumor markers of CA-125, CA19-9 and Carcinoma Embryonic Antigen (CEA) decreasing to normal levels.…”

“…The feasibility and effectiveness of IMRT in treating patients with advanced ovarian cancer suggest that IMRT is a novel therapeutic option for treating advanced EOC [46,47,50]. Advanced EOC has a high rate of recurrence, and consolidation therapies including total abdominal irradiation (WAR) have had limited success.…”